Health

#SFHS2616262AFrance adds B. Braun PLASMAFIT DUAL MOBILITY hip implant components to reimbursable products list

🇫🇷France··Other·Low Impact·View source ↗

AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.

🇬🇧 English

This measure adds several PLASMAFIT DUAL MOBILITY hip replacement components from B. Braun Medical to France’s reimbursable medical products list. The listed items include metal and vitamin E-enriched polyethylene inserts, as well as cementless acetabular cups used in double-mobility hip systems. The practical effect is that hospitals, orthopedic surgeons, and purchasing teams can use these specific components in reimbursed hip replacement procedures when the covered indications are met. Coverage is limited to cementless use, mainly for patients at high risk of hip dislocation or for revision surgeries involving repeated dislocations. Reimbursement is set to run until 15 July 2031 for the listed references.

AI-generated summary. May contain errors. Refer to official sources for legal decisions.

Key Changes

  • Adds B. Braun Medical’s PLASMAFIT DUAL MOBILITY hip implant components to France’s reimbursable products list
  • Covers specified metal inserts, vitamin E-enriched polyethylene inserts, and cementless acetabular cups
  • Limits reimbursement to defined high-risk primary hip replacements and revision surgeries, with coverage ending on 15 July 2031

Obligations

What this law requires

medium

Use the PLASMAFIT DUAL MOBILITY system only for cementless hip joint replacement when seeking reimbursement under the listed coverage.

hospitalsorthopedic surgeonshealthcare purchasing teams
Coverage ends on 15 July 2031
operational
medium

Limit reimbursed first-intention arthroplasty use of PLASMAFIT DUAL MOBILITY to patients with a very high risk of dislocation, including severe neurological disorders, neuropsychiatric disorders, addictions, or major neuromuscular deficiencies.

hospitalsorthopedic surgeons
Coverage ends on 15 July 2031
operational
medium

Limit reimbursed revision arthroplasty use of PLASMAFIT DUAL MOBILITY to cases involving recurrent dislocations or patients with a high risk of dislocation.

hospitalsorthopedic surgeons
Coverage ends on 15 July 2031
operational
low

When using the DUAL MOBILITY insert under reimbursement code 3195837, use only covered references NV1010Z, NV1011Z, NV1012Z, NV1013Z, NV1014Z, NV1015Z, NV1016Z, or NV1017Z.

hospitalshealthcare purchasing teamsorthopedic surgeons
Coverage ends on 15 July 2031
operational
low

When using the VITELENE insert for 22.2 mm heads under reimbursement code 3187387, use only covered references NV1030E, NV1031E, or NV1032E.

hospitalshealthcare purchasing teamsorthopedic surgeons
Coverage ends on 15 July 2031
operational

Affected Parties

Hospitals and orthopedic surgery centersOrthopedic surgeons+3 more…

Tags

medical devices,hip implants,reimbursement